GTBP Beginning To Turn Heads!
It’s clear that companies like Gilead don’t have any plans on slowing down their M&A trend anytime soon. In fact, in a conference call regarding its latest deal with Kite, John Milligan, Gilead’s CEO, said that the company is “quite interested in things that would augment cellular therapy.”
Therefore, many investors have started to search for “the next Kite” opportunity…(GTBP) is beginning to turn heads!
U.K.’s Brexit Disbelief Challenges Biopharma Deal
The United Kingdom government disclosed the highly anticipated deal with the life sciences sector and the document showed shared some vague details of investments intended by drug developers such as GlaxoSmithKline.
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $950,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to December 31, 2018 to publicly disseminate information about (GTBP). We own zero shares.